Influenza
Conditions
Interventions
Test group:Jinpingfeng Capsule
Sponsors
Zhejiang Provincial Center for Disease Control and Prevention
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-65 years, gender unrestricted. (2) No influenza-like symptoms at the time of enrollment (axillary temperature <37.3°C or ear temperature <37.5°C); and no occurrence of any of the following clinical manifestations within 24 hours prior to enrollment: fever, headache, muscle/joint pain, sore throat, dry cough, nasal congestion, runny nose, productive cough, shortness of breath, chest pain, chills, shivering, fatigue, loss of appetite, nausea, vomiting, diarrhea. Participants presenting with any of the above symptoms will be excluded. (3) Voluntarily participate in this study and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Individuals who have received the seasonal influenza vaccine in the current study season; (2) Severe or critical cases requiring hospitalization; (3) Other serious clinical conditions necessitating inpatient or monitored treatment; (4) Severe comorbidities affecting major organs or systems such as the heart, brain, or respiratory system; (5) Pregnant women, women in the perinatal period, lactating women, or individuals planning to conceive during the study period; (6) Individuals with known allergies to any components of Jinfeng Capsule; (7) Individuals currently using immunosuppressants; (8) Patients in the acute exacerbation phase of chronic respiratory diseases; (9) Individuals with screening results showing serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal (i.e., ALT > 3 × ULN or AST > 3 × ULN), or serum creatinine (SCr) levels exceeding 1.5 times the upper limit of normal (i.e., SCr > 1.5 × ULN); (10) Individuals who have experienced influenza-like symptoms within the two months prior to enrollment; (11) Individuals who have taken antiviral medications (such as Jinhua Qinggan, Lianhua Qingwen, oseltamivir, etc.) within the seven days prior to enrollment; (12) Individuals who have used antipyretic analgesics or antihistamines within the 72 hours prior to enrollment; (13) Individuals who have participated in other drug clinical trials within one month prior to the screening examination; (14) Individuals deemed unsuitable for participation by the investigator, such as those regularly consuming other health supplements or foods with similar effects or immune-boosting properties as Jinfeng Capsule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laboratory-confirmed influenza incidence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Influenza-like illness (ILI) incidence rate; | — |
Countries
China
Contacts
Public ContactYan Zou
Zhejiang Provincial Center for Disease Control and Prevention
Outcome results
None listed